Evolus, Inc.
EOLSNASDAQHealthcare● Active
$6.68
+$0.01(+0.15%)
Market Cap$439909737
P/E Ratio—
52W High$10.62
52W Low$3.86
Evolus, Inc. (EOLS) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
EOLS · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 4, 2026EPS Actual
-$0.10
Est. -$0.14 · +28.6%
Revenue
$0.07B
Est. $0.07B · +0.8%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 4, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
EOLS reports quarterly as a NASDAQ-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | -$0.01 | — | — | — | $0.08B | — |
| ▲ Q2 FY2026 | May 4, 2026 | -$0.14 | -$0.10 | +28.6% | $0.07B | $0.07B | +0.8% |
| ▼ Q1 FY2026 | Mar 3, 2026 | $0.06 | $0.04 | -26.3% | $0.09B | $0.09B | +0.9% |
| ▲ Q4 FY2025 | Nov 5, 2025 | -$0.19 | -$0.14 | +26.3% | $0.07B | $0.09B | -23.0% |
| ▼ Q3 FY2025 | Aug 5, 2025 | -$0.09 | -$0.24 | -166.7% | $0.07B | $0.09B | -18.7% |
| ▼ Q2 FY2025 | May 7, 2025 | -$0.10 | -$0.18 | -80.0% | $0.07B | $0.08B | -17.3% |
| ▼ Q1 FY2025 | Mar 4, 2025 | $0.02 | $0.01 | -50.0% | $0.08B | $0.07B | +10.0% |
| ▼ Q4 FY2024 | Nov 6, 2024 | -$0.08 | -$0.19 | -137.5% | $0.06B | $0.08B | -20.6% |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
-$0.01
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 4, 2026Beat
EPS Actual
-$0.10
EPS Est.
-$0.14
EPS Surpr.
+28.6%
Revenue
$0.07B
Q1 FY2026
Mar 3, 2026Miss
EPS Actual
$0.04
EPS Est.
$0.06
EPS Surpr.
-26.3%
Revenue
$0.09B
Q4 FY2025
Nov 5, 2025Beat
EPS Actual
-$0.14
EPS Est.
-$0.19
EPS Surpr.
+26.3%
Revenue
$0.07B
Q3 FY2025
Aug 5, 2025Miss
EPS Actual
-$0.24
EPS Est.
-$0.09
EPS Surpr.
-166.7%
Revenue
$0.07B
Q2 FY2025
May 7, 2025Miss
EPS Actual
-$0.18
EPS Est.
-$0.10
EPS Surpr.
-80.0%
Revenue
$0.07B
Q1 FY2025
Mar 4, 2025Miss
EPS Actual
$0.01
EPS Est.
$0.02
EPS Surpr.
-50.0%
Revenue
$0.08B
Q4 FY2024
Nov 6, 2024Miss
EPS Actual
-$0.19
EPS Est.
-$0.08
EPS Surpr.
-137.5%
Revenue
$0.06B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.21 | $0.22 | $0.23 | 1 |
| Q3 FY2028 | $0.08 | $0.08 | $0.08 | 1 |
| Q2 FY2028 | $0.11 | $0.11 | $0.11 | 1 |
| Q1 FY2028 | $0.05 | $0.05 | $0.05 | 1 |
| Q4 FY2027 | $0.15 | $0.15 | $0.16 | 1 |
| Q3 FY2027 | $0.01 | $0.01 | $0.01 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.1B | $0.1B | $0.1B | 2 |
| Q3 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q2 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q1 FY2028 | $0.1B | $0.1B | $0.1B | 2 |
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 3 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 4, 2026 | +28.6% | $5.33 | $5.58 | +4.69% |
| ▼ Q1 FY2026 | Mar 3, 2026 | -26.3% | $4.29 | $4.13 | -3.73% |
| ▲ Q4 FY2025 | Nov 5, 2025 | +26.3% | $6.41 | $6.81 | +6.24% |
| ▼ Q3 FY2025 | Aug 5, 2025 | -166.7% | $9.11 | $8.91 | -2.20% |
| ▼ Q2 FY2025 | May 7, 2025 | -80.0% | $11.61 | $11.76 | +1.29% |
| ▼ Q1 FY2025 | Mar 4, 2025 | -50.0% | $14.34 | $14.35 | +0.07% |
| ▼ Q4 FY2024 | Nov 6, 2024 | -137.5% | $16.49 | $16.81 | +1.94% |
| ▼ Q3 FY2024 | Jul 31, 2024 | -23.1% | $12.19 | $12.42 | +1.89% |
Q2 FY2026+4.69%
Report Date
May 4, 2026
EPS Beat/Miss
+28.6%
Price Before
$5.33
Price After
$5.58
Q1 FY2026-3.73%
Report Date
Mar 3, 2026
EPS Beat/Miss
-26.3%
Price Before
$4.29
Price After
$4.13
Q4 FY2025+6.24%
Report Date
Nov 5, 2025
EPS Beat/Miss
+26.3%
Price Before
$6.41
Price After
$6.81
Q3 FY2025-2.20%
Report Date
Aug 5, 2025
EPS Beat/Miss
-166.7%
Price Before
$9.11
Price After
$8.91
Q2 FY2025+1.29%
Report Date
May 7, 2025
EPS Beat/Miss
-80.0%
Price Before
$11.61
Price After
$11.76
Q1 FY2025+0.07%
Report Date
Mar 4, 2025
EPS Beat/Miss
-50.0%
Price Before
$14.34
Price After
$14.35
Q4 FY2024+1.94%
Report Date
Nov 6, 2024
EPS Beat/Miss
-137.5%
Price Before
$16.49
Price After
$16.81
Q3 FY2024+1.89%
Report Date
Jul 31, 2024
EPS Beat/Miss
-23.1%
Price Before
$12.19
Price After
$12.42
Avg Beat Reaction+5.46%
Avg Miss Reaction-0.12%
Beat Rate2 / 8 quarters
Largest Move+6.24% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: EOLS ends December
Evolus, Inc. (EOLS) most recently reported earnings on May 4, 2026 for Q2 FY2026, posting EPS of $-0.10 — beating the analyst consensus of $-0.14 by +28.6%. The next EOLS earnings date is expected around September 1, 2026.
Each quarter, investors track EOLS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. EOLS revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
EOLS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
EOLS earnings · 5 questionsEvolus, Inc.'s next earnings report is expected around September 1, 2026. EOLS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; EOLS historically reports after market close (AMC).
EOLS earnings datewhen is EOLS earningsEOLS next earnings datewhen does EOLS report earningsEOLS earnings calendar
▸ Source: FMP · Evolus, Inc. SEC filings · US GAAP · Evolus, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026